TheraPsil Unveils MDMA-Assisted Psychotherapy Training Program


VANCOUVER, BC, September 25th, 2023 – TheraPsil, an non-profit organization dedicated to advancing legal access to psychedelic-assisted psychotherapy in Canada, is pleased to announce its latest endeavour, which has just received Board approval: an MDMA-Assisted Psychotherapy Training Program. 

With over 500 healthcare professionals trained in its Fundamentals of Psilocybin-Assisted Psychotherapy training programs, TheraPsil has built a network of passionate psychedelic healthcare practitioners and is now poised to captivate the field by addressing the surging demand for training and treatment in the realm of MDMA-assisted psychotherapy for trauma survivors. 

Curriculum development and rollout will be under the leadership of Dr. Ingrid Pacey, a distinguished TheraPsil trainer who served as the Principal Investigator of the MAPS Phase 2 MDMA trial in Vancouver. Dr. Pacey had this to say: 

“Psychotherapists need to be trained to work with a wide variety of psychedelics to best serve the needs of their prospective patients.”

With this announcement, TheraPsil embarks on a new chapter of growth and innovation, enriching its mission to deliver safe, efficacious therapies for those grappling with mental health challenges. Notably, this expansion extends TheraPsil’s advocacy efforts to include not only psilocybin but also MDMA, through the Special Access Program (SAP) for patients in medical need.

Yasmeen deRosenroll, TheraPsil’s Director of Training & Operations, shared her enthusiasm for this momentous development:

“We are thrilled to unveil the expansion of our training programs, designed to offer comprehensive support to our valued stakeholders. Our organization is deeply dedicated to achieving clinical excellence while embracing a patient-centred philosophy. We are excited to extend our support to a wider array of trauma survivors, enhancing access to legal MDMA-Assisted Psychotherapy through Health Canada’s SAP program, and steadfastly addressing the diverse needs of the patients we serve.”

The pilot phase of this training is expected to launch in early 2024 and will cater to practitioners who have successfully completed the didactic component of TheraPsil’s Fundamentals of Psilocybin-Assisted Psychotherapy training program. Interested practitioners are invited to apply for this program by filling out this application page.


For media inquiries or additional information, please contact:

John Gilchrist

TheraPsil Communications Manager



About TheraPsil

TheraPsil is a non-profit organization committed to legalizing medical access to psychedelic therapy for patients in need. Established in 2019, TheraPsil champions the cause of regulated psychedelics, providing invaluable support for training, research, and clinical services in this groundbreaking field. For more information, please visit

Share this post